- Global Pharma News & Resources

Anemia Treatment Market is Expected to Generate Around USD 40,915 million by 2025

Zion Market Research has published a new report titled “Anemia Treatment Market By Anemia (Iron Deficiency, Sickle Cell, Pernicious, Thalassemia, and Hemolytic), By Drug (Bone Marrow Stimulants, Gene Therapy, Iron Chelating Agents, Corticosteroids, Supplements, and Immunotherapy), and By Distribution Channel (Retail Pharmacies, E-Commerce, and Hospital Pharmacies): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global anemia treatment market was USD 24,673 million in 2018 and is expected to generate around USD 40,915 million by 2025, growing at a CAGR of around 7.5% between 2019 and 2025.

Anemia is caused by the lack of red blood cells or hemoglobin in the human body. Red blood cells are responsible for carrying oxygen from the lungs to the rest of the body. Anemia symptoms include weakness, feeling tired, shortness of breath, and restrictions in physical activities, which may vary according to age, altitude, smoking habits, sex, and pregnancy status. Anemia, if left untreated, may even cause death.

According to the WHO, in 2018, about 56% of people globally were affected by anemia. Anemia can be effectively treated with a proper treatment method. The high rate of nutritional deficiency is among the most important driving factors of the anemia treatment market. According to the WHO, 50% of anemic cases are caused by iron deficiency due to low iron intake. Growing baby booming population and increasing chronic diseases and disorders are fuelling the anemia treatment market. Improper nutritional diet in underdeveloped countries also contributes to this market.

The anemia treatment market is fragmented on the basis of anemia, drug, and distribution channel. By anemia, the anemia treatment market includes iron deficiency, sickle cell, pernicious, thalassemia, and hemolytic. The iron deficiency accounted for the largest share in the anemia treatment market globally. Sickle cell anemia held the second position in terms of market share globally. The main variables responsible for these segments’ growth are high expansion rate and accessible drug therapy expenses more than other types.

By drug, the market is divided into corticosteroids, gene therapy, bone marrow stimulants, iron chelating agents, immunotherapy, and supplements. In 2018, corticosteroids and immunosuppressant accounted for the largest shares of more than 50% globally. The increasing anemia awareness and the rising initiatives by non-government organizations and government, rising anemia prevalence, and advancements in the research activities of the anemia treatment industry are driving these segments.

On the basis of the distribution channel, the anemia treatment market comprises e-commerce, hospital pharmacies, and retail pharmacies. The retail pharmacy accounted for a major share of the global market. In terms of growth rate, e-commerce segment is expected to register the highest CAGR globally.

Get Free Sample of this Research Report

North America is projected to dominate the anemia treatment market globally, owing to the early introduction of highly developed treatment options, increasing nutritional deficiency due to changing lifestyle, and constant introduction of favorable reimbursement policies. The Asia Pacific anemia treatment market is anticipated to show a notable growth rate over the forecast time period.

Some key players of global anemia treatment market are Pfizer, Johnson and Johnson, Novartis, Roche, Amgen, Bayer, GlaxoSmithKline, Teva Pharmaceuticals, Novo Nordisk, CSL, AMAG Pharmaceuticals, Rockwell Medicines, Akebia Therapeutics, and Vifor Pharma.

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 31-Aug-2020